As of 2025-04-30, the Relative Valuation of Syndax Pharmaceuticals Inc (SNDX) is (128.93) USD. This relative valuation is based on P/E multiples. With the latest stock price at 13.70 USD, the upside of Syndax Pharmaceuticals Inc based on Relative Valuation is -1041.1%.
The range of the Relative Valuation is (105.14) - (130.78) USD.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 28.4x - 43.5x | 37.9x |
| Forward P/E multiples | 24.3x - 35.3x | 31.7x |
| Fair Price | (105.14) - (130.78) | (128.93) |
| Upside | -867.5% - -1054.6% | -1041.1% |
| Date | P/E |
| 2025-04-25 | -3.60 |
| 2025-04-24 | -3.59 |
| 2025-04-23 | -3.51 |
| 2025-04-22 | -3.49 |
| 2025-04-21 | -3.22 |
| 2025-04-17 | -3.11 |
| 2025-04-16 | -2.98 |
| 2025-04-15 | -3.06 |
| 2025-04-14 | -3.03 |
| 2025-04-11 | -3.01 |
| 2025-04-10 | -2.84 |
| 2025-04-09 | -3.11 |
| 2025-04-08 | -2.85 |
| 2025-04-07 | -2.97 |
| 2025-04-04 | -3.04 |
| 2025-04-03 | -3.36 |
| 2025-04-02 | -3.50 |
| 2025-04-01 | -3.24 |
| 2025-03-31 | -3.32 |
| 2025-03-28 | -3.56 |
| 2025-03-27 | -3.66 |
| 2025-03-26 | -3.54 |
| 2025-03-25 | -3.63 |
| 2025-03-24 | -3.71 |
| 2025-03-21 | -3.70 |
| 2025-03-20 | -3.81 |
| 2025-03-19 | -3.54 |
| 2025-03-18 | -3.40 |
| 2025-03-17 | -3.52 |
| 2025-03-14 | -3.50 |
| 2025-03-13 | -3.54 |
| 2025-03-12 | -3.54 |
| 2025-03-11 | -3.51 |
| 2025-03-10 | -3.38 |
| 2025-03-07 | -3.62 |
| 2025-03-06 | -3.86 |
| 2025-03-05 | -3.91 |
| 2025-03-04 | -3.88 |
| 2025-03-03 | -4.18 |
| 2025-02-28 | -4.22 |
| 2025-02-27 | -4.12 |
| 2025-02-26 | -4.20 |
| 2025-02-25 | -4.11 |
| 2025-02-24 | -4.23 |
| 2025-02-21 | -4.42 |
| 2025-02-20 | -4.32 |
| 2025-02-19 | -3.98 |
| 2025-02-18 | -3.95 |
| 2025-02-14 | -4.03 |
| 2025-02-13 | -4.07 |